Cargando…
Correction to: Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials
Autores principales: | Schultz, Neil M, Shore, Neal D, Chowdhury, Simon, Klotz, Laurence H, Concepcion, Raoul S, Penson, David F, Karsh, Lawrence I, Yang, Hongbo, Brown, Bruce A, Barlev, Arie, Flanders, Scott C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6166278/ https://www.ncbi.nlm.nih.gov/pubmed/30285696 http://dx.doi.org/10.1186/s12894-018-0397-5 |
Ejemplares similares
-
Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials
por: Schultz, Neil M., et al.
Publicado: (2018) -
Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial
por: Penson, David F., et al.
Publicado: (2021) -
Correction: Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial
por: Penson, David F., et al.
Publicado: (2021) -
Treatment registry for outcomes in patients with castration-resistant prostate cancer (TRUMPET): a methodology for real-world evidence and research
por: Penson, David F, et al.
Publicado: (2016) -
Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials
por: Antonarakis, Emmanuel S., et al.
Publicado: (2023)